DPH.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 saus. 2024 @ 19:38):

Stats
Šios dienos apimtis	192 108
Vidutinė apimtis	1.36M
Rinkos kapitalizacija	4.40B
EPS	£0 ( 2024-02-25 )
Last Dividend	£12.50 ( 2023-03-09 )
Next Dividend	£0 ( N/A )
P/E	-154.64
ATR14	£15.19 (0.39%)

Tūris Koreliacija

Ilgas: 0.33 (neutral)

Trumpas: 0.95 (very strong)

Signal:(71.495) Expect same movement, but be aware

Dechra Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BUR.L	0.808

10 Labiausiai neigiamai susiję koreliacijos
DMGT.L	-0.834

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Dechra Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.41
( neutral )

0.77
( moderate )

0.42
( neutral )

0.62
( weak )

0.17
( neutral )

-0.41
( neutral )

Dechra Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	£761.50M
Bruto pelnas:	£426.30M (55.98 %)
EPS:	£-0.240

FY	2022
Pajamos:	£761.50M
Bruto pelnas:	£426.30M (55.98 %)
EPS:	£-0.240

FY	2022
Pajamos:	£681.80M
Bruto pelnas:	£384.80M (56.44 %)
EPS:	£0.540

FY	2021
Pajamos:	£608.00M
Bruto pelnas:	£345.90M (56.89 %)
EPS:	£0.538

Financial Reports:

No articles found.

Dechra Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£32.89 (N/A)	£12.50 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Dechra Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.80 - low (26.53%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£1.133	2001-03-07
Last Dividend	£12.50	2023-03-09
Next Dividend	£0	N/A
Payout Date	2023-04-13
Next Payout Date	N/A
# dividends	45	--
Total Paid Out	£356.25	--
Avg. Dividend % Per Year	0.54%	--
Score	2.05	--
Div. Sustainability Score	3.80
Div.Growth Potential Score	0
Div. Directional Score	1.261	--

Next Divdend (Est)
(2024-07-08)

£12.38 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

2.05

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2001	£0	0.00%
2002	£0	0.00%
2003	£0	0.00%
2004	£0	0.00%
2005	£0	0.00%
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.50	0.92%
2019	£31.60	1.51%
2020	£34.29	1.17%
2021	£40.50	1.14%
2022	£44.89	0.94%
2023	£12.50	0.48%
2024	£0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PNS.L	Dividend King	2023-06-29	Semi-Annually	31	3.82%
FSTA.L	Dividend Knight	2023-06-22	Annually	33	0.95%
AFM.L	Dividend Knight	2023-09-07	Annually	8	1.57%
THS.L	Dividend Knight	2023-06-08	Annually	7	3.10%
LOK.L	Dividend King	2023-05-04	Semi-Annually	18	34.89%
CML.L	Dividend King	2023-08-03	Semi-Annually	32	2.93%
RKT.L	Dividend Knight	2023-08-03	Semi-Annually	23	1.95%
HEFT.L	Dividend Knight	2023-06-01	Semi-Annually	53	1.20%
ATS.L	Dividend Knight	2023-08-24	Semi-Annually	26	0.94%
UPR.L	Dividend Junior	2023-09-28	Annually	5	0.34%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0366	1.500	-0.733	-1.099	[0 - 0.5]
returnOnAssetsTTM	-0.0178	1.200	-0.593	-0.711	[0 - 0.3]
returnOnEquityTTM	-0.0349	1.500	-1.499	-2.25	[0.1 - 1]
payoutRatioTTM	-1.853	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	2.85	0.800	0.735	0.588	[1 - 3]
quickRatioTTM	1.333	0.800	6.87	5.49	[0.8 - 2.5]
cashRatioTTM	0.454	1.500	8.59	10.00	[0.2 - 2]
debtRatioTTM	0.321	-1.500	4.64	-6.96	[0 - 0.6]
interestCoverageTTM	0.767	1.000	-0.827	-0.827	[3 - 30]
operatingCashFlowPerShareTTM	0.559	2.00	9.81	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.358	2.00	9.82	10.00	[0 - 20]
debtEquityRatioTTM	0.668	-1.500	7.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.564	1.000	3.93	3.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0225	1.000	-1.551	-1.551	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.126	1.000	-0.411	-0.411	[0.2 - 2]
assetTurnoverTTM	0.485	0.800	-0.0986	-0.0788	[0.5 - 2]
Total Score				3.80

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-157.77	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.0349	2.50	-0.964	-2.25	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.358	2.00	9.88	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.559	2.00	9.81	10.00	[0 - 30]
payoutRatioTTM	-1.853	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	-1 577.69	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0835	1.000	-0.412	0	[0.1 - 0.5]
Total Score				-1.282

Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.